FilingReader Intelligence
Glenmark Pharmaceuticals hit by $37.75m US litigation settlement
August 14, 2025 at 07:07 PM UTC•By FilingReader AI
Glenmark Pharmaceuticals reported flat revenue growth of 0.6% to INR 32,644 million in Q1, with adjusted profit of INR 3,129 million hit by a $37.75 million US litigation settlement.
The company approved transferring its Consumer Care business to a new wholly-owned subsidiary for approximately INR 240.40 crores.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Appointment of Ms. Patricia Andrews as an Additional Director (Non-Executive, Independent Director) of the Company.August 14, 2025 at 12:29 PM UTC
Approved the transfer of the Company''s Consumer Care business to its newly incorporated wholly owned subsidiary Glenmark Consumer Care Limited.August 14, 2025 at 12:43 PM UTC
Please find attached Press Release and Management Discussion & Analysis of the Company for the first quarter ended June 30, 2025August 14, 2025 at 12:11 PM UTC
Outcome of the Board Meeting held on 14th August, 2025August 14, 2025 at 12:25 PM UTC
Approved the appointment of M/s. Walker Chandiok & Co., LLP as the Statutory Auditors of the CompanyAugust 14, 2025 at 12:32 PM UTC
Approved the appointment of M/s. Rauthan & Associates LLP as the Secretarial Auditors of the CompanyAugust 14, 2025 at 12:36 PM UTC
Investor Presentation - Q1 FY 25-26August 14, 2025 at 12:51 PM UTC
BSE:GLENMARK•Bombay Stock Exchange
News Alerts
Get instant email alerts when Glenmark Pharmaceuticals publishes news
Free account required • Unsubscribe anytime